Charlotte Robinson

DocwireNews

California-based medical device company Toku received Breakthrough Device designation from the US Food and Drug Administration (FDA) for its MyKidneyAI technology.MyKidneyAI uses artificial intelligence (AI) to analyze retinal images collected at routine eye exams to detect increased chronic kidney disease (CKD) risk in people with diabetes. Most patients with diabetes are not routinely screened for CKD, so the disease often goes undetected until it has advanced and simple interventions are no longer effective.The AI system works by taking photos of the retina, the only part of the cardiovascular system that can be photographed, to look for signs of microvascular disease, a primary contributor to CKD. With the breakthrough designation, Toku is now able to work with eye care companies to distribute its devices across the United States.&ldquo;Given the potential impact of this technology for people with CKD, we are extremely proud to have advanced MyKidneyAI so quickly,&rdquo; said Ehsan Vaghefi, chief executive officer of Toku.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

AI Technology to Detect CKD in Retinal Images Gets Boost From FDA

Chronic Kidney Disease

MyKidenyAI, which detects elevated CKD risk in people with diabetes using retinal images, received Breakthrough Device designation from the FDA.

AI Technology to Detect CKD in Retinal Images Gets Boost From FDA 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe